<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p184" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_184{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_184{left:306px;bottom:30px;}
#t3_184{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_184{left:346px;bottom:30px;}
#t5_184{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_184{left:517px;bottom:30px;}
#t7_184{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_184{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_184{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_184{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_184{left:35px;bottom:777px;letter-spacing:0.18px;}
#tc_184{left:35px;bottom:754px;letter-spacing:0.06px;word-spacing:0.12px;}
#td_184{left:549px;bottom:761px;letter-spacing:-0.01px;}
#te_184{left:35px;bottom:731px;letter-spacing:0.07px;word-spacing:0.12px;}
#tf_184{left:35px;bottom:707px;letter-spacing:0.13px;word-spacing:0.05px;}
#tg_184{left:35px;bottom:684px;letter-spacing:0.1px;word-spacing:-0.22px;}
#th_184{left:35px;bottom:661px;letter-spacing:0.13px;word-spacing:0.06px;}
#ti_184{left:35px;bottom:638px;letter-spacing:0.16px;word-spacing:-0.08px;}
#tj_184{left:35px;bottom:614px;letter-spacing:0.16px;word-spacing:0.02px;}
#tk_184{left:35px;bottom:591px;letter-spacing:0.13px;word-spacing:0.05px;}
#tl_184{left:35px;bottom:568px;letter-spacing:0.1px;word-spacing:-1.04px;}
#tm_184{left:35px;bottom:545px;letter-spacing:0.04px;word-spacing:-0.76px;}
#tn_184{left:35px;bottom:522px;letter-spacing:0.07px;word-spacing:0.11px;}
#to_184{left:35px;bottom:498px;letter-spacing:-0.05px;}
#tp_184{left:35px;bottom:459px;letter-spacing:0.07px;word-spacing:0.11px;}
#tq_184{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:-0.29px;}
#tr_184{left:35px;bottom:413px;letter-spacing:0.05px;word-spacing:-1.1px;}
#ts_184{left:35px;bottom:390px;letter-spacing:0.11px;word-spacing:0.08px;}
#tt_184{left:35px;bottom:366px;letter-spacing:0.15px;word-spacing:0.04px;}
#tu_184{left:35px;bottom:343px;letter-spacing:0.13px;word-spacing:0.06px;}
#tv_184{left:35px;bottom:320px;letter-spacing:0.07px;word-spacing:-0.71px;}
#tw_184{left:296px;bottom:327px;letter-spacing:-0.01px;}
#tx_184{left:319px;bottom:320px;letter-spacing:0.16px;word-spacing:0.03px;}
#ty_184{left:35px;bottom:297px;letter-spacing:0.09px;word-spacing:-0.23px;}
#tz_184{left:35px;bottom:273px;letter-spacing:0.14px;word-spacing:0.04px;}
#t10_184{left:35px;bottom:250px;letter-spacing:0.04px;word-spacing:0.15px;}
#t11_184{left:35px;bottom:210px;letter-spacing:0.22px;word-spacing:-0.04px;}
#t12_184{left:35px;bottom:187px;letter-spacing:0.05px;word-spacing:0.14px;}
#t13_184{left:35px;bottom:163px;letter-spacing:0.12px;word-spacing:-0.48px;}
#t14_184{left:35px;bottom:140px;letter-spacing:0.09px;word-spacing:0.1px;}
#t15_184{left:35px;bottom:117px;letter-spacing:0.06px;word-spacing:0.12px;}
#t16_184{left:35px;bottom:94px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t17_184{left:35px;bottom:71px;letter-spacing:0.12px;word-spacing:0.07px;}
#t18_184{left:452px;bottom:78px;letter-spacing:-0.01px;}
#t19_184{left:475px;bottom:71px;letter-spacing:-0.1px;word-spacing:0.29px;}
#t1a_184{left:618px;bottom:777px;letter-spacing:0.15px;word-spacing:-0.41px;}
#t1b_184{left:618px;bottom:754px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1c_184{left:618px;bottom:731px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1d_184{left:618px;bottom:707px;letter-spacing:0.11px;word-spacing:0.2px;}
#t1e_184{left:618px;bottom:684px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1f_184{left:618px;bottom:661px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1g_184{left:618px;bottom:638px;letter-spacing:0.17px;word-spacing:-0.76px;}
#t1h_184{left:618px;bottom:614px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t1i_184{left:618px;bottom:591px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1j_184{left:618px;bottom:568px;letter-spacing:0.13px;word-spacing:-0.61px;}
#t1k_184{left:618px;bottom:545px;letter-spacing:0.16px;word-spacing:-0.5px;}
#t1l_184{left:618px;bottom:522px;letter-spacing:0.08px;word-spacing:-0.03px;}
#t1m_184{left:618px;bottom:498px;letter-spacing:0.19px;}
#t1n_184{left:618px;bottom:475px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1o_184{left:618px;bottom:452px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1p_184{left:618px;bottom:430px;letter-spacing:0.07px;word-spacing:-0.59px;}
#t1q_184{left:618px;bottom:407px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1r_184{left:618px;bottom:383px;letter-spacing:0.19px;}
#t1s_184{left:683px;bottom:391px;letter-spacing:-0.01px;}
#t1t_184{left:618px;bottom:343px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1u_184{left:618px;bottom:320px;letter-spacing:0.14px;word-spacing:-0.09px;}
#t1v_184{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1w_184{left:618px;bottom:273px;letter-spacing:0.08px;word-spacing:0.23px;}
#t1x_184{left:618px;bottom:250px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1y_184{left:618px;bottom:227px;letter-spacing:0.08px;word-spacing:-0.45px;}
#t1z_184{left:618px;bottom:204px;letter-spacing:0.07px;word-spacing:-0.01px;}
#t20_184{left:618px;bottom:181px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t21_184{left:618px;bottom:157px;letter-spacing:0.04px;word-spacing:0.14px;}
#t22_184{left:618px;bottom:134px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t23_184{left:618px;bottom:111px;letter-spacing:-0.02px;}
#t24_184{left:656px;bottom:118px;letter-spacing:-0.01px;}
#t25_184{left:680px;bottom:111px;letter-spacing:0.15px;word-spacing:0.04px;}
#t26_184{left:618px;bottom:88px;letter-spacing:0.07px;word-spacing:0.12px;}
#t27_184{left:618px;bottom:64px;letter-spacing:0.18px;word-spacing:0.01px;}
#t28_184{left:952px;bottom:64px;}
#t29_184{left:968px;bottom:64px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2a_184{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_184{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_184{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_184{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_184{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_184{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_184{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_184{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_184{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts184" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg184Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg184" style="-webkit-user-select: none;"><object width="1210" height="935" data="184/184.svg" type="image/svg+xml" id="pdf184" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_184" class="t s0_184">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_184" class="t s1_184">© </span>
<span id="t3_184" class="t s0_184">(NCCN </span>
<span id="t4_184" class="t s1_184">© </span>
<span id="t5_184" class="t s0_184">), All rights reserved. NCCN Guidelines </span>
<span id="t6_184" class="t s1_184">® </span>
<span id="t7_184" class="t s0_184">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_184" class="t s2_184">NCCN Guidelines Version 4.2024 </span>
<span id="t9_184" class="t s2_184">Head and Neck Cancers </span>
<span id="ta_184" class="t s3_184">MS-43 </span>
<span id="tb_184" class="t s4_184">consists of 2.12 Gy/fraction daily (Monday–Friday) for 33 fractions to all </span>
<span id="tc_184" class="t s4_184">areas of gross disease, also to a total dose of approximately 70 Gy. </span>
<span id="td_184" class="t s5_184">562 </span>
<span id="te_184" class="t s4_184">Low-risk subclinical disease, such as in the low neck, can be treated </span>
<span id="tf_184" class="t s4_184">separately to a dose of 44–50 Gy at 2.0 Gy/fraction or can be treated </span>
<span id="tg_184" class="t s4_184">simultaneously within the same plan as for gross disease to doses of 54– </span>
<span id="th_184" class="t s4_184">56 Gy at 1.6–1.7 Gy/fraction. For areas considered to be at intermediate </span>
<span id="ti_184" class="t s4_184">risk, slightly higher doses such as 59.4–63 Gy in 1.8–2.0 Gy/fraction can </span>
<span id="tj_184" class="t s4_184">be given to regions of the skull base and neck in proximity to gross </span>
<span id="tk_184" class="t s4_184">disease. The total doses and fractionation should be prescribed in </span>
<span id="tl_184" class="t s4_184">relationship to each other and the overall schedule as part of an integrated </span>
<span id="tm_184" class="t s4_184">plan to address the varying areas at risk. If separate sequentially delivered </span>
<span id="tn_184" class="t s4_184">radiation plans are used, the combined dosimetry of all plans should be </span>
<span id="to_184" class="t s4_184">evaluated. </span>
<span id="tp_184" class="t s4_184">Some recent initiatives have attempted to reduce treatment volumes. For </span>
<span id="tq_184" class="t s4_184">instance, in a randomized multi-center phase 3 trial from China (N = 446), </span>
<span id="tr_184" class="t s4_184">three-year regional relapse-free survival did not significantly differ between </span>
<span id="ts_184" class="t s4_184">patients with N0-1 NPC who received elective RT to the ipsilateral upper </span>
<span id="tt_184" class="t s4_184">neck (sparing the uninvolved lower neck) and patients who received </span>
<span id="tu_184" class="t s4_184">standard whole-neck irradiation (97.7% [95% CI, 95.7–99.7] vs. 96.3% </span>
<span id="tv_184" class="t s4_184">[95% CI, 93.8–98.8], respectively). </span>
<span id="tw_184" class="t s5_184">563 </span>
<span id="tx_184" class="t s4_184">Acute radiation-related toxic effects </span>
<span id="ty_184" class="t s4_184">were generally similar between the study arms, though rates of some late </span>
<span id="tz_184" class="t s4_184">toxicities favored the elective upper-neck RT arm, specifically </span>
<span id="t10_184" class="t s4_184">hypothyroidism, skin toxicity, dysphagia, and neck tissue damage. </span>
<span id="t11_184" class="t s4_184">Definitive-style dose-fractionation schedules are frequently used for </span>
<span id="t12_184" class="t s4_184">patients with de novo metastatic disease who achieve response to initial </span>
<span id="t13_184" class="t s4_184">induction therapy and then become eligible for consolidative irradiation of </span>
<span id="t14_184" class="t s4_184">the gross primary and nodal disease. However, for other metastatic </span>
<span id="t15_184" class="t s4_184">scenarios, a variety of palliative schedules may be used (see the </span>
<span id="t16_184" class="t s4_184">algorithms for these schedules). For treatment volumes following induction </span>
<span id="t17_184" class="t s4_184">chemotherapy, there are conflicting recommendations, </span>
<span id="t18_184" class="t s5_184">564 </span>
<span id="t19_184" class="t s4_184">but a common </span>
<span id="t1a_184" class="t s4_184">practice is to reduce the volumes receiving the highest dose according to </span>
<span id="t1b_184" class="t s4_184">shrinkage of tumor that respects anatomic boundaries. A randomized </span>
<span id="t1c_184" class="t s4_184">clinical trial from China included 212 patients with stage III–IVB NPC who </span>
<span id="t1d_184" class="t s4_184">all received 2 cycles of induction chemotherapy and then had curative </span>
<span id="t1e_184" class="t s4_184">intent IMRT combined with concurrent systemic therapy. The patients </span>
<span id="t1f_184" class="t s4_184">were randomized to have their gross tumor volumes treated either </span>
<span id="t1g_184" class="t s4_184">according to pre-induction extent or post-induction extent; these received </span>
<span id="t1h_184" class="t s4_184">a prescription dose of 70 Gy in 33 fractions to the delineated gross </span>
<span id="t1i_184" class="t s4_184">disease, with 64 Gy given to areas of post-induction shrinkage from the </span>
<span id="t1j_184" class="t s4_184">original tumor extent in the post-induction group. At a median follow-up of </span>
<span id="t1k_184" class="t s4_184">98.4 months, the 5-year estimated overall, progression-free, locoregional </span>
<span id="t1l_184" class="t s4_184">recurrence-free, and distant metastasis-free survival rates in the pre- and </span>
<span id="t1m_184" class="t s4_184">post-induction groups were 78.2% versus 83.3%, 72.0% versus 78.1%, </span>
<span id="t1n_184" class="t s4_184">90.2% versus 93.5%, and 78.1% versus 82.1%, respectively. The pre- </span>
<span id="t1o_184" class="t s4_184">induction group had a significantly higher incidence of xerostomia and </span>
<span id="t1p_184" class="t s4_184">hearing damage. The post-induction groups had significant improvements </span>
<span id="t1q_184" class="t s4_184">in cognitive function, dry mouth, sticky saliva, and feeling ill on QOL </span>
<span id="t1r_184" class="t s4_184">surveys. </span>
<span id="t1s_184" class="t s5_184">565 </span>
<span id="t1t_184" class="t s4_184">Reirradiation of locoregionally recurrent NPC should be conducted with </span>
<span id="t1u_184" class="t s4_184">careful attention to the previously delivered radiation plan and performed </span>
<span id="t1v_184" class="t s4_184">when complete surgical extirpation is not possible. Because of the </span>
<span id="t1w_184" class="t s4_184">anatomic location of NPC in proximity to the optic structures, brain, </span>
<span id="t1x_184" class="t s4_184">brainstem, and spinal cord, there can be high risk with reirradiation of </span>
<span id="t1y_184" class="t s4_184">injury to critical neural structures. In a phase 3 open label trial from China, </span>
<span id="t1z_184" class="t s4_184">patients with locally advanced recurrent NPC (N = 144) were randomized </span>
<span id="t20_184" class="t s4_184">to receive hyperfractionated RT (prescription dose of 65 Gy in 54 fractions, </span>
<span id="t21_184" class="t s4_184">twice daily with a time interval of at least 6 hours) or RT with standard </span>
<span id="t22_184" class="t s4_184">fractionation (prescription dose of 60 Gy in 27 fractions, given once per </span>
<span id="t23_184" class="t s4_184">day). </span>
<span id="t24_184" class="t s5_184">566 </span>
<span id="t25_184" class="t s4_184">Three-year OS rates were greater in the hyperfractionation arm </span>
<span id="t26_184" class="t s4_184">compared to the standard fractionation arm (74.6% vs. 55.0%, </span>
<span id="t27_184" class="t s4_184">respectively; HR, 0.54; 95% CI, 0.33–0.88; </span><span id="t28_184" class="t s6_184">P </span><span id="t29_184" class="t s4_184">= .014). Grade 5 late </span>
<span id="t2a_184" class="t s7_184">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
